Thea Veitonmäki1,2, Teemu J Murtola1,3, Liisa Määttänen4, Kimmo Taari5, Ulf-Håkan Stenman6, Teuvo L J Tammela1,3, Anssi Auvinen2. 1. Department of Urology, Tampere University Hospital, Tampere, Finland. 2. School of Health Sciences, University of Tampere, Tampere, Finland. 3. School of Medicine, University of Tampere, Tampere, Finland. 4. Finnish Cancer Registry, Helsinki, Finland. 5. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 6. Department of Clinical Chemistry, Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND: Growing evidence suggests that aspirin is associated with decreased prostate cancer (PCa) mortality. The effect of other NSAID use on risk of PCa death remains controversial. We examined prostate cancer survival among aspirin and other NSAID users in the Finnish Prostate Cancer Screening Trial. METHODS: A total of 6,537 men were diagnosed with prostate cancer in 1996-2009 among the 80,144 men in the trial and 617 died from prostate cancer during the median follow-up of 7.5 years after the diagnosis. Prescription drug purchases information was obtained from the national reimbursement database. We calculated hazard ratios and 95% confidence intervals for PCa-specific survival using multivariable-adjusted Cox regression analysis separately for NSAID and aspirin usage before and after the diagnosis. RESULTS: We observed an increased risk of PCa death associated with both pre- and post-diagnostic NSAID usage (HR 1.30, 95%CI 1.07-1.58 and HR 2.09, 95%CI 1.75-2.50, respectively). An increasing risk trend was observed by cumulative dose and intensity of NSAID use. When the last three years were excluded from the analysis, the death risk diminished to a protective level (HR 0.42, 95%CI 0.34-0.51 and HR 0.30 95%CI 0.24-0.39). Aspirin use was not significantly associated with prostate cancer survival. CONCLUSIONS: The survival decrease among NSAID users is likely explained by symptomatic treatment of metastatic pain in patients with advanced PCa. However, results of the lag time analysis support previous findings of a possible preventative action of NSAIDs.
BACKGROUND: Growing evidence suggests that aspirin is associated with decreased prostate cancer (PCa) mortality. The effect of other NSAID use on risk of PCa death remains controversial. We examined prostate cancer survival among aspirin and other NSAID users in the Finnish Prostate Cancer Screening Trial. METHODS: A total of 6,537 men were diagnosed with prostate cancer in 1996-2009 among the 80,144 men in the trial and 617 died from prostate cancer during the median follow-up of 7.5 years after the diagnosis. Prescription drug purchases information was obtained from the national reimbursement database. We calculated hazard ratios and 95% confidence intervals for PCa-specific survival using multivariable-adjusted Cox regression analysis separately for NSAID and aspirin usage before and after the diagnosis. RESULTS: We observed an increased risk of PCa death associated with both pre- and post-diagnostic NSAID usage (HR 1.30, 95%CI 1.07-1.58 and HR 2.09, 95%CI 1.75-2.50, respectively). An increasing risk trend was observed by cumulative dose and intensity of NSAID use. When the last three years were excluded from the analysis, the death risk diminished to a protective level (HR 0.42, 95%CI 0.34-0.51 and HR 0.30 95%CI 0.24-0.39). Aspirin use was not significantly associated with prostate cancer survival. CONCLUSIONS: The survival decrease among NSAID users is likely explained by symptomatic treatment of metastatic pain in patients with advanced PCa. However, results of the lag time analysis support previous findings of a possible preventative action of NSAIDs.
Authors: Cindy Ke Zhou; Sarah E Daugherty; Linda M Liao; Neal D Freedman; Christian C Abnet; Ruth Pfeiffer; Michael B Cook Journal: Cancer Prev Res (Phila) Date: 2017-05-15
Authors: Lauren M Hurwitz; Corinne E Joshu; John R Barber; Anna E Prizment; Mara Z Vitolins; Miranda R Jones; Aaron R Folsom; Misop Han; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-28 Impact factor: 4.254
Authors: Sarah N C Gimenes; Daiana S Lopes; Patrícia T Alves; Fernanda V P V Azevedo; Lara Vecchi; Luiz R Goulart; Thais C S Rodrigues; André L Q Santos; Vera L de C Brites; Thaise L Teixeira; Cláudio V da Silva; Matheus H Dias; Samuel C Teixeira; Renata S Rodrigues; Kelly A G Yoneyama; Ricardo A Oliveira; Veridiana de M Rodrigues Journal: Sci Rep Date: 2017-08-01 Impact factor: 4.379
Authors: Pete T T Kinnunen; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen Journal: BMC Cancer Date: 2017-08-29 Impact factor: 4.430
Authors: Peter C Elwood; Janet E Pickering; Gareth Morgan; Julieta Galante; Alison L Weightman; Delyth Morris; Marcus Longley; Malcolm Mason; Richard Adams; Sunil Dolwani; John Chia W K; Angel Lanas Journal: PLoS One Date: 2018-09-25 Impact factor: 3.240